Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A global initiative to deliver precision health in diabetes.

Nature medicine·2024
Same author

Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.

Annales d'endocrinologie·2020
Same author

Trans-ethnic analysis of metabochip data identifies two new loci associated with BMI.

International journal of obesity (2005)·2018
Same author

New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine.

Clinical pharmacology and therapeutics·2017
Same author

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Clinical pharmacology and therapeutics·2017
Same author

Pharmacogenetic Implementation Lessons From the "Real World".

Clinical pharmacology and therapeutics·2016

Related Experiment Video

Updated: May 26, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Predicting clopidogrel response using DNA samples linked to an electronic health record.

J T Delaney1, A H Ramirez, E Bowton

  • 1Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.

Clinical Pharmacology and Therapeutics
|December 23, 2011
PubMed
Summary

Genetic variants in ABCB1 and CYP2C19 predict cardiac events in patients taking clopidogrel after heart attack or stent placement. These findings replicate previous research in a real-world setting using electronic health records.

Related Experiment Videos

Last Updated: May 26, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Genetics

Background:

  • Clopidogrel is a common antiplatelet medication used after myocardial infarction (MI) and percutaneous coronary intervention (PCI).
  • Genetic variants in ABCB1 and CYP2C19 are known to affect clopidogrel efficacy.
  • PON1 variants have been linked to stent thrombosis, but real-world validation is needed.

Purpose of the Study:

  • To replicate the association of ABCB1, CYP2C19, and PON1 variants with recurrent cardiac events in a real-world patient population treated with clopidogrel.
  • To evaluate the utility of electronic health records (EHRs) for pharmacogenomic research.

Main Methods:

  • Utilized BioVU, a DNA repository linked to de-identified EHRs.
  • Identified patients treated with clopidogrel after MI and/or PCI.
  • Compared genetic variants in cases (recurrent cardiac events) and controls (no recurrent events).

Main Results:

  • CYP2C19*2 (HR 1.54, P = 0.003) and ABCB1 (HR 1.28, P = 0.018) variants were significantly associated with recurrent cardiac events.
  • No significant association was found for PON1 variants (HR 0.91, P = 0.370).
  • Findings support the use of EHRs for pharmacogenomic studies.

Conclusions:

  • Genetic variants in CYP2C19 and ABCB1 are confirmed predictors of clopidogrel treatment outcomes in a real-world setting.
  • PON1 variants were not associated with recurrent cardiovascular events in this cohort.
  • EHR-based pharmacogenomic studies are feasible and valuable for validating genetic associations.